Sotera’s Earnings Call Contradictions: X-Ray Facility Timeline and Sterigenics Growth Outlook Clash

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $1.236B (full year outlook raised to $1.254B, representing 5.25% to 6.75% constant currency growth)
• EPS: $0.95 to $1.01 per diluted share (adjusted EPS outlook raised from $0.93 to $1.10)
• Operating Margin: Adjusted EBITDA margin of 51.6%, expanded 36 basis points YOY

Guidance:

• Revenue for 2026 expected to be $1.254B, representing 5.25% to 6.75% constant currency growth.
• EBITDA growth for 2026 expected to be 5.75% to 7.25%.
• Adjusted EPS for 2026 expected to be $0.95 to $1.01 per diluted share.
• Sterigenics segment expected to deliver mid-to-high single-digit constant currency revenue growth.
• Nordion segment expected to deliver low-to-mid single-digit constant currency revenue growth.
• Nelson Labs segment expected to deliver low-to-mid single-digit constant currency revenue growth.
• Capital expenditures for 2026 expected to be $200M to $225M.
• Net leverage ratio expected to improve to 2-3x.

Business Commentary:

Strong Financial Performance:

• Sotera Health reported revenue growth of 8% on a constant currency basis for the second quarter, with adjusted EBITDA growing 8.7% over the last year.
• The growth was driven by Sterigenics' momentum, Nordion's execution, and Nelson Labs exceeding expectations, reflecting broad-based strength across the portfolio.

Segment Revenue Growth:

• Sterigenics achieved 7% constant currency revenue growth, while Nordion grew by 60 basis points of segment income margin expansion and 7% constant currency revenue growth.
• These results were driven by favorable pricing, increased volume, and strategic customer engagements.

Increased Full-Year Outlook:

• Sotera Health raised its full-year 2026 revenue growth outlook to 5.25% to 6.75% constant currency growth, with adjusted EBITDA expected to grow between 5.75% to 7.25%.
• This adjustment was based on strong first-half performance, customer demand stability, and favorable pricing trends.

Leadership and Strategic Focus:

• Alton Shader assumed the role of CEO, emphasizing a customer-focused culture and leveraging cross-business unit synergies.
• His strategies aim to enhance customer partnerships and drive consistent growth, supported by a strong foundation built by the previous leadership.

Capital Allocation and Leverage:

• The company reported a net leverage ratio improvement to 3x, with strong liquidity positioning it to support growth initiatives.
• Capital expenditures totaled $48 million, focusing on capacity expansion and facility upgrades to sustain long-term growth.

Sentiment Analysis:

Overall Tone: Positive

• "We delivered a strong quarter, highlighted by solid execution across our businesses... we are raising our full year outlook." "We are confident in our ability to execute on our priorities and to create long-term value for our stakeholders." "We've seen a lot of similar indicators... we continue to like our position and our guides as well."

Q&A:

• Question from Chris (BMO): Can you share more detail on the drivers of the improvement in Nelson Labs' quarter? Is this primarily lapping EAS headwinds, and what visibility do you have?
  Response: Growth driven by new customer wins and strong underlying demand; visibility supports confidence for the back half of the year.

• Question from Abby (Goldman Sachs): What are your top priorities as CEO, and what are you seeing from a competitive standpoint?
  Response: Priorities are understanding the business, assessing talent, building customer focus, and developing cross-business unit solutions. Competition is stable; demand is strong and guides are confident.

• Question from Luke (Barclays): How do you differentiate from competitors, and what is the market share dynamic between EO and other modalities?
  Response: Sotera is viewed as higher-end and more customer-focused; competition is stable but not slowing demand. The company is making progress on integrated solutions.

• Question from Ryan (RBC): Any update on the validation testing pipeline for Nelson Labs and the cadence?
  Response: Pipeline is healthy with opportunities expected to contribute to growth in the back half of the year.

• Question from Casey (Woodring): What gives you confidence to raise the high end of guidance after beating last year?
  Response: Confidence comes from strong Q2 performance, an uptick in Sterigenics growth in the second half, and the fact that some H2 revenue shifted to H1 was achieved above plan.

• Question from Brendan (Citi): Can you touch on the increased EBITDA outlook for Sterigenics and Nordion?
  Response: Sterigenics growth boosted by tailwinds like favorable shutdown schedules, a new large customer outsourcing, and new X-ray facility revenue. Nordion growth remains low-to-mid single digits.

• Question from Dave (Jefferies): Regarding Nelson Labs margins and the three-to-four percent pricing target, how is progress on pricing for EO enhancements?
  Response: Strong pricing in Sterigenics reflects customer recognition of value. The company is on track to get pricing tied to EO enhancements and expects total company pricing to be within the 3-4% long-term target.

• Question from Brett (KeyBank): What are the opportunities and efforts for cross-business unit activities, and where is the greatest penetration opportunity?
  Response: Cross-business unit work is complementary and adds value; the greatest opportunity is providing integrated solutions that delight customers and increase satisfaction.

• Question from Joseph (Piper Sandler): Is there any change in the pricing ceiling for Sterigenics in 2027 given competition or inflation?
  Response: No material change in competitive pricing environment; the company expects to continue pricing for the value provided, consistent with the 3-4% target.

• Question from Michael (Wolf Research): What is the litigation update on New Mexico, Georgia, and California?
  Response: New Mexico settled in July for immaterial impact. Georgia appellate process expected in Spring/Summer 2026. California trial expected in January or April 2027.

Contradiction Point 1

Status and Timeline of the Second X-ray Facility Project

Contradiction on whether the second X-ray facility project is back on track for 2026 or delayed to 2027/2028.

What are your key concerns regarding the earnings report, David Windley (Jefferies)? - David Windley (Jefferies)

2026Q2: The second X-ray facility project had been on a brief pause. Now it is fully back on track, and progress is being made with the team. It is expected to be finished towards the end of 2026, contributing to the CapEx step-up this year. - John Lyons(CFO)

What is the current status of the second facility that was delayed pending client discussions and commitments? - Michael Polark (Wolfe Research)

2026Q2: The second X-ray facility project... It is now back on track, with completion expected towards the end of 2027 or early 2028. - Alton Shader(CEO)

Contradiction Point 2

Sterigenics Second-Half 2026 Growth Outlook

Contradiction in the drivers and confidence level for an uptick in Sterigenics growth in H2.

Casey (J.P. Morgan) - Casey (J.P. Morgan)

2026Q2: Our guidance philosophy is to be realistic. The raised guidance reflects: ... 2) An expected uptick in Sterigenics growth in the second half (driven by favorable shutdown schedules, a large customer transitioning from insourcing, and new X-ray capacity)... - Alton Shader(CEO)

What factors are contributing to the improved visibility and increased confidence in the guidance? - Chris Charlton (BMO)

2026Q2: Sterigenics delivered 7% constant currency revenue growth, with volume contributing 2.7%. Demand is stable across the portfolio... Confidence in the second-half guidance is based on strong customer discussions and backlog. - Alton Shader(CEO)

Contradiction Point 3

Sterigenics Growth and Pricing Outlook

Guidance for Sterigenics growth and pricing stability appears inconsistent.

Brendan Diggins (Citi) - Brendan Diggins (Citi)

2026Q2: The increased EBITDA guidance is driven by... confidence in an uptick in second-half growth (vs. first half) due to favorable shutdown schedules, a large customer transitioning from insourcing, and new X-ray capacity. 2) Nordion's continued strong execution, maintaining low-to-mid single-digit revenue growth for the full year... - John Lyons(CFO)

Will you discuss the increased EBITDA guide, Nordian, and the improved Stereogenics outlook? - Matt Sykes (William Blair)

2026Q1: The guide reflects a tougher comparison, as Q2 2025 was the strongest quarter of growth. There is no expected slowdown in underlying performance. - Jonathan M. Lyons(CFO)

Contradiction Point 4

Progress and Status of Cross-Business Unit (XBU) Collaboration

Assessment of XBU performance and growth potential contradicts previous optimism.

Abigail (on behalf of Evie Kozlowski, Goldman Sachs) - Abigail (on behalf of Evie Kozlowski, Goldman Sachs)

2026Q2: My immediate priorities are... 4) Explore more cross-business unit synergies (e.g., "one Sotera" offerings) to improve service and solutions. - Alton Shader(CEO)

What are your top priorities for driving additional synergies between the businesses and commercial strategy updates? - Ryan Houston (RBC Capital Markets)

2026Q1: XBU performed well in Q1, with growth and positive customer satisfaction scores. The embedded labs within Nelson and Sterigenics are executing well, and XBU is well-situated for continued progress. - Michael B. Petras, Jr.(CEO)

Contradiction Point 5

Sterigenics Growth Cadence and Timing

Contradiction on the timing and drivers of Sterigenics' volume growth.

Casey (J.P. Morgan) - Casey (J.P. Morgan)

2026Q2: We have confidence in an uptick in Sterigenics growth in the second half... Our guidance philosophy is to be realistic. - Alton Shader(CEO)

What factors led to the increased guidance, and what gives you confidence in future performance? - Luke Sergott (Barclays) - question by Sam:

2025Q4: The slow start in 2026 is due to some shutdowns and weather impacts. Despite this, the full-year guidance of mid- to high single-digit growth is maintained. - Michael Petras(CEO)